Tag Archives: PD-L1

November, 2016

October, 2016

July, 2016

June, 2016

  • 27 June

    Merck Gets CHMP Positive Opinion for Keytruda as Advanced NSCLC Treatment

    KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of …

  • 24 June

    Epizyme and Genentech Partner to Assess Drug Combo in NHL

    CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, announced today it has entered into a collaboration agreement with Genentech, a member of the Roche Group, to conduct a clinical trial to investigate the anti-cancer effects of Epizyme’s EZH2 inhibitor, tazemetostat, …

March, 2016

January, 2016